Immuneering Corp (IMRX) Form 8-K — May 15, 2026
Immuneering (IMRX) reported Q1 2026 results with a net loss of $13.5 million, narrowing from $15.0 million in the prior year, while maintaining $198.6 million in cash with a runway into 2029. The company announced that new survival data from its Phase 2a trial of atebimetinib plus mGnP in first-line metastatic pancreatic cancer will be presented in an oral session at the 2026 ASCO Annual Meeting on June 1.
Key figures
- Revenue
- 0
- Total Assets
- 214809790
- Cash Position
- 198600000
- Ga Expenses
- 4682495
- Rd Expenses
- 10645222
- Runway Year
- 2029
- Shares Outstanding
- 64688915
- Weighted Avg Shares
- 64658809
Price after filing
1 day: 0.0%7 days: +1.6%30 days: -19.8%
Close on the filing date to close N calendar days later (from $5.14). Historical, not a forecast.
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.